Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status
Yu-Ling Cen
The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorMei-Ling Qi
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorHai-Gang Li
The Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorYi Su
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorLi-Juan Chen
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorYing Lin
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorWei-Qing Chen
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorXiao-Ming Xie
The Cancer Center, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorCorresponding Author
Lu-Ying Tang
The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
The Third Affiliated Hospital, Sun Yat-Sen University, 600 Tianhe Rd, Guangzhou 510630, China.
The School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Rd, Guangzhou 510080, China.
Search for more papers by this authorCorresponding Author
Dr. Ze-Fang Ren
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
The Third Affiliated Hospital, Sun Yat-Sen University, 600 Tianhe Rd, Guangzhou 510630, China.
The School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Rd, Guangzhou 510080, China.
Search for more papers by this authorYu-Ling Cen
The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorMei-Ling Qi
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorHai-Gang Li
The Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorYi Su
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorLi-Juan Chen
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorYing Lin
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorWei-Qing Chen
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorXiao-Ming Xie
The Cancer Center, Sun Yat-Sen University, Guangzhou, China
Search for more papers by this authorCorresponding Author
Lu-Ying Tang
The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
The Third Affiliated Hospital, Sun Yat-Sen University, 600 Tianhe Rd, Guangzhou 510630, China.
The School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Rd, Guangzhou 510080, China.
Search for more papers by this authorCorresponding Author
Dr. Ze-Fang Ren
The School of Public Health, Sun Yat-Sen University, Guangzhou, China
The Third Affiliated Hospital, Sun Yat-Sen University, 600 Tianhe Rd, Guangzhou 510630, China.
The School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Rd, Guangzhou 510080, China.
Search for more papers by this authorAbstract
Genetic polymorphisms of fibroblast growth factor receptor 2 (FGFR2) have been demonstrated to be associated with breast cancer risk, presumably through elevation of FGFR2 expression. Fibroblast growth factor 1 (FGF1) and RNA binding protein fox-1 homolog 2 (RBFOX2), which are functionally related to FGFR2, may also associate with breast cancer risk. We investigated the associations between breast cancer risk and the polymorphisms of FGFR2 rs2981582, FGF1 rs250108, and RBFOX2 rs2051579 among 839 incident breast cancer cases and 863 age-matched controls in the Guangzhou Breast Cancer Study. Stratified odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by estrogen receptor (ER)/progesterone receptor (PR) status using multivariate logistic regression. FGFR2 rs2981582 was confirmed to be significantly associated with the risk of ER-positive but not ER-negative breast cancer. In contrast, FGF1 rs250108 was significantly associated with the risk of ER-negative breast cancer (OR (95% CI) = 1.68 (1.20–2.35) for CT + TT vs. CC genotype) but not ER-positive breast cancer. CA + AA genotypes at RBFOX2 rs2051579 were associated with a reduced risk of ER-negative (0.71 (0.52–0.97)) but not ER-positive breast cancer compared to the CC genotype. Similar results were observed when differentiating breast cancer cases by PR status. Neither of the pairs between the three SNPs had a significant interaction on breast cancer risk. Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer. © 2012 Wiley Periodicals, Inc.
Supporting Information
Additional supporting information may be found in the online version of this article.
Filename | Description |
---|---|
mc21979-sm-0001-SupTabs-S1-S4.doc130.5 KB | Supporting Tables S1-S4 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087–1093.
- 2 Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870–874.
- 3 Kawase T, Matsuo K, Suzuki T, et al. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan. Int J Cancer 2009; 125: 1946–1952.
- 4 Liang J, Chen P, Hu Z, et al. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008; 29: 2341–2346.
- 5 Boyarskikh UA, Zarubina NA, Biltueva JA, et al. Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. Eur J Hum Genet 2009; 17: 1688–1691.
- 6 Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008; 6: e108.
- 7 Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69: 565–572.
- 8 Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139–149.
- 9 Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 2010; 10: 116–129.
- 10 Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694–15700.
- 11 Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007; 75: 831–842.
- 12 Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008; 6: 435–445.
- 13 Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 2011; 30: 603–611.
- 14 Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740–746.
- 15 Baraniak AP, Chen JR, Garcia-Blanco MA. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Mol Cell Biol 2006; 26: 1209–1222.
- 16 Sueta A, Ito H, Kawase T, et al. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat 2012; 132: 711–721.
- 17 Wang P, Dai M, Xuan W, et al. SNP Function Portal: A web database for exploring the function implication of SNP alleles. Bioinformatics 2006; 22: e523–e529.
- 18 Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008; 4: e1000054.
- 19 Reeves GK, Travis RC, Green J, et al. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA 2010; 304: 426–434.
- 20 Su Y, Tang LY, Chen LJ, et al. Joint effects of febrile acute infection and an interferon-gamma polymorphism on breast cancer risk. PLoS ONE 2012; 7: e37275.
- 21 Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–145.
- 22 He JR, Tang LY, Yu DD, et al. Epstein-Barr virus and breast cancer: Serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett 2011; 309: 128–136.
- 23 Rothman KJ. The estimation of synergy or antagonism. Am J Epidemiol 1976; 103: 506–511.
- 24 Ren ZF, Liu WS, Qin HD, et al. Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong, China. Cancer Epidemiol 2010; 34: 419–424.
- 25 Zhang L, Kharbanda S, Chen D, et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997; 15: 2093–2108.
- 26 Zhang L, Kharbanda S, McLeskey SW, Kern FG. Overexpression of fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes. Cancer Res 1999; 59: 5023–5029.
- 27 Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008; 14: 8000–8009.
- 28 Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2000; 18: 573–580.
- 29 Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66: 273–280.
- 30 Hishikawa Y, Tamaru N, Ejima K, Hayashi T, Koji T. Expression of keratinocyte growth factor and its receptor in human breast cancer: Its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol 2004; 67: 455–464.
- 31 Tamaru N, Hishikawa Y, Ejima K, et al. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 2004; 84: 1460–1471.
- 32 Miki T, Bottaro DP, Fleming TP, et al. Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 1992; 89: 246–250.
- 33 Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159–178.
- 34 Yoshimura N, Sano H, Hashiramoto A, et al. The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 1998; 89: 28–34.
- 35 Venables JP, Klinck R, Koh C, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670–676.
- 36 Lapuk A, Marr H, Jakkula L, et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 2010; 8: 961–974.
- 37 Prudovsky I, Savion N, Zhan X, et al. Intact and functional fibroblast growth factor (FGF) receptor-1 trafficks near the nucleus in response to FGF-1. J Biol Chem 1994; 269: 31720–31724.
- 38 Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004; 6: 240–245.
- 39 Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 1558–1568.